Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Amendment to the SEK subscription price of Loudspring´s rights issue

Loudspring OyjCompany release, inside information18 February 2022, 10:15(EET) Loudspring amends the SEK subscription price of its rights issue (released on February 17th 2022) according to instructions received from Euroclear Sweden.  The subscription price per Offer Share in Sweden has been modified to include only two decimals according to instructions received from Euroclear Sweden. The new subscription price per offer share in Sweden is SEK 1,09 (previously SEK 1,096). The subscription price per Offer Share in Finland has not been modified. The amended terms and conditions

BioStock: DexTech Medical’s CEO on the company’s platform technology

DexTech Medical develops drug candidates in oncology that are based on the CDC platform GuaDex, where different substances are combined with the carbohydrate molecule dextran. The company will soon advance into the clinical phase in multiple myeloma with the main candidate OsteoDex, which has shown promising phase II clinical results in metastatic castration-resistant prostate cancer. BioStock contacted DexTech’s CEO Anders R Holmberg to find out more.Read the full article at biostock.se: https://www.biostock.se/en/2022/02/dextech-medicals-ceo-on-the-companys-platform-technology/ This

Getinge’s new modular room system helps hospitals create safe and functional workplaces

Getinge is today launching the new and extended modular room system Getinge IN2 – an intelligent solution for creating interconnected, sustainable and efficient workplaces in hospital departments around the world.“Getinge IN2, the successor to our Variop and Variward systems, is designed intuitively to evolve with cutting-edge technologies in the Operating Room (OR), Intensive Care Unit (ICU) and Central Sterile Supply Departments (CSSD). It complements nicely our existing range of equipment to provide complete, integrated turnkey solutions,” says Philippe Rocher, President at Getinge South

Nexam is recruiting for continued rapid expansion in wind power Hires Dane Momcilovic as responsible for PET applications

Nasdaq First North-listed Nexam Chemical has recruited Dane Momcilovic as Business Manager for the growing PET foam business area. Dane Momcilovic comes most recently from Polygiene and has previously been development manager at Diab. The assignment involves being responsible for further developing the PET foam business and expanding it with more products and customers. Dane Momcilovic will take up the post on March 1.Nexam Chemical helps plastics manufacturers around the world to improve their products - both in terms of durability and function - and thus competitiveness. Dane

Sanolium Interim report 4/2021

Revenues in the fourth quarter amounted to 196.6 MSEK, representing growth of 17.6%Support and maintenance fees constitute the largest share of the revenue. License revenues and Professional Services revenues are attributable to the development of the existing product as well as the Sussa project. Adjusted EBITDA in the fourth quarter amounted to 28.3 (12.2) MSEK resulting in an adjusted EBITDA margin of 14.4 (7.3) %. Employee related expenses amounted to 136.3 (129.3) MSEK, representing an increase of 5.4%. The number of full-time employees rose to 747 in the fourth quarter, an

Year-end report January - December 2021 S2Medical AB (publ)

SUMMARY OF THE INTERIM REPORT During the fourth quarter, sales in regular wound healing products amounted to MSEK 1.4 (0.1) and increased on a full-year basis by 261% compared with 2020. The Group's Net sales during the quarter amounted to MSEK 1.6 (4.9). Net sales throughout the year amounted to MSEK 7.7 (25.6). During the fourth quarter of the previous year, the Company had increased turnover as a result of sales of medical consumables with the aim of preventing the spread of COVID-19. DEVELOPMENT WITHIN THE GROUP, OCTOBER – DECEMBER 2021 · Net sales within the Company's

AddSecure takes home a bronze medal in the Swedish Championships in Employer Branding

Fast-growing IoT company, AddSecure, received an award for its initiative "One company, one culture" during the Magnet Awards yesterday, a competition for Sweden's best and most efficient in employer communication.Magnet Awards  is a non-profit project that annually organizes the Swedish Championships in Employer Branding, a competition that pays tribute to employers who make a difference. The competition, which is the largest of its kind, highlights the best companies in Sweden in terms of employer communication. AddSecure  was awarded

Read original

The Nomination Committee's proposal for the election of Board members

The Nomination Committee of Micro Systemation AB, which consists of Erik Ivarsson (appointed by  AB Grenspecialisten) David Zaudy (appointed by Cervantes Capital) and Christian Hellman (appointed by Edastra AB), has decided to submit the following proposals to the 2022 Annual General Meeting regarding the number of Board members and the election of Board members. The Nomination Committee proposes that the number of Board members on the Board be reduced by one person and thus amount to five members. The Nomination Committee proposes the re-election as Board members of Bernt Ingman,

Invitation to Cereno Scientific webcast: Clinical Phase II study with drug candidate CS1 in PAH

Cereno Scientific (XSAT: CRNO B) invites investors, financial analysts, and media to a webcast presentation on February 25, 2022. The presentation will focus on the Phase II study of drug candidate CS1 in the rare disease pulmonary arterial hypertension (PAH). Chief Executive Officer, Sten R. Sörensen and Chief Medical Officer Dr. Björn Dahlöf from Cereno will be joined by Dr. Raymond Benza, Principal Investigator for the study and Dr. Philip Adamson, Vice President and Chief Medical Officer at study collaborator Abbott.  The presentations will cover the background, design, and plan for the

SAPA Series with Emma Ridderstad

It was not so long ago that parallel worlds were merely the staple of science fiction writers. Today however, the nascent technology of virtual and augmented reality is for the first time making it possible to talk about the merging of the digital and physical into a single, hybrid universe. Propelled by the booming gaming sector, virtual reality has in the last few years started to spill over into industries ranging from education and human resources, to construction and design. And yet, more than half a century after the very first VR headset was created in the US for military

DSRT: Desert Control H2 2021 Report and interim Financial Results | Webcast presentation 25 February 10:00 CET

ISSUER DESERT CONTROL AS Desert Control H2 2021 Report and Financial Results will be released on Friday25 February 2021 at 0800 AM Central European Time (Oslo).Report and presentation will be available at www.desertcontrol.comWebcast presentation in English will be hosted on Friday 25 February at 10.00 AMCentral European Time.Registration:https://desertcontrol.zoom.us/webinar/register/7816451668620/WN_gNoNVqAgSH6UrdqhZbkjwwAfter the presentation, there will be a moderated question and answers session.Questions for Q&A can be submitted in advance toerling.rasmussen@

Scandinavian ChemoTech’s subsidiary signs its first commercial contract for the US veterinary market

ChemoTech’s Animal Care division Vetiqure AB signs a contract with FloridaWild Veterinary Hospital (“FloridaWild”) in Deland, Florida as a direct result of a successful trade show in Orlando, which generated many leads.The contract with FloridaWild includes access to our vetIQure™ TSE device during an initial evaluation period and a commercial purchase of our treatment kits. In addition to the purchase of the treatment kits an order for the device will be placed following a successful evaluation. The joint goal with the agreement is to establish a Centre of Excellence with FloridaWild where

Inhalation Sciences signs IRS contract worth 584,000 SEK with leading nanotech company

Inhalation Research Services, ISAB’s contract research organization, has signed a contract worth 584 000 SEK with a leading nanotechnology company that specializes in developing new inhalable nanoporous particles for drug delivery. The client has chosen ISAB’s unique intratracheal in vivo exposure module for its research project, due to its proven precision and reliability.The development of nanoparticles for drug delivery is a fast-moving and high-potential research area within the pharmaceutical industry. A leading company in the field has now chosen Inhalation Research Services for a

Hynion and Hyrex launches floating hydrogen station for leisure boats

Hynion AS and Hyrex AS last year set up a JV for establishing hydrogen stations for refuelling leisure boats with zero-emission fuel, and are now presenting innovative fueling solutions.- Hydrogen will be important for the decarbonisation of the transport sector in Norway, not least in the maritime sector. Although other modes of transport account for larger emissions than leisure boats, this is a significant segment. The Norwegian authorities have given clear signals that emissions from leisure boats should be reduced by 50 %. The establishment of floating hydrogen stations will improve

BioStock: Strong start to 2022 for Respiratorius

2022 looks to be an eventful year for Lund-based Respiratorius, which released its report for the fourth quarter on Tuesday. The company has started the PK study with the new formulation of VAL001, while announcing a new capital injection and plans to spin off its respiratory project. BioStock contacted the company's CEO Johan Drott to dig a little deeper into the quarterly report and get his view on the interesting situation the company is in at the moment.Read the full interview with Johan Drott at biostock.se: https://www.biostock.se/en/2022/02/strong-start-to-2022-for-respiratorius/

Hired a creative director before the upcoming global launch of Cricket Manager Pro

on February 18, 2022 at 08:30 Wicket Gaming AB (publ) has hired Philip Cederman as the new Creative Director. Philip Cederman is especially hand-picked ahead of the upcoming global launch of Cricket Manager Pro.Philip comes most recently from Mud Studios, where he has worked for the past 4 years as Technical Director, Group Leader and Retouch Artist. He has over 10 years of experience in IT technical roles as well as graphic design and leadership. At Wicket Gaming, Philip will, among other things, work to raise the graphic profile for Wicket Gaming and the company's products, which

Year-End Report October – December 2021

(Oslo, 18 February 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the year-end report for the period 1 October – December 31, 2021. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Genetic Analysis CEO Ronny Hermansen comments:“The year of 2021 has passed, and we can look back on an eventful year filled with milestones like an oversubscribed IPO, successful listing at Spotlight Stock Market, the signing of IMD as a new high-volume lab in Europe, and the receival of a research grant of

ORGANOCLICK AB (PUBL) PUBLISH YEAR END REPORT FOR 2021

"Sales of OrganoTex® more than doubled during the quarter, as with the full year. We expect the very strong sales growth of OrganoTex® to continue in 2022, driven by all our new customers and ongoing international expansion."Translation from CEO Mårten Hellbergs comments to the Interim Report. Q4, 1 October - 31 December 2021 The Group compared with 2020 » Net revenue amounted to SEK 17.95 (18.20) million » The gross margin (after variable costs) amounted to 43.8 (40.9) % » EBITDA amounted to SEK -7.65 (-6.03) million » Cash-flow from operating activities amounted to SEK -

Year-end report January – December 2021

The period in summary January 1 – December 31, 2021 –      The European Commission granted in August a Marketing Authorisation for Strangvac within the European Union. During September the Veterinary Medicines Directorate (VMD) of the United Kingdom also granted a Marketing Authorisation for Strangvac within the UK. –      In April Intervacc announced an exclusive distribution agreement with Dechra Pharmaceuticals PLC, to commercialize Strangvac in Europe, excluding the Nordic and Baltic countries where Intervacc will market and sell Strangvac directly. –      Intervacc was

Episurf Medical’s implants receive national regulatory approval in Hong Kong

Episurf Medical (NASDAQ: EPIS B) today announces that the Department of Health (Medical Device Division) in Hong Kong has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Hong Kong market. Included in the approval is also the ankle device Talus Osteotomy Guide. The approval follows a review process.  “Previously we were able to act in this market thanks to our CE marked products, but it brought on various limitations. This national approval is important, and it will help us increase the market acceptance in the region even further”, says Michael

Notice of the Annual General Meeting of Ratos AB (publ)

Shareholders of Ratos AB (publ), reg.nr 556008-3585, are hereby invited to the Annual General Meeting to be held at Tuesday, March 22, 2022. The AGM will be conducted pursuant to so called mail-in procedures, meaning that no shareholders will attend the AGM in person or through proxy. Instead, shareholders can participate in the AGM by voting and submitting questions in advance pursuant to the instructions described below.In order to participate in the AGM, a shareholder shall:   a. be registered in the register of shareholders maintained by Euroclear Sweden AB as of Monday, March 14,

Veoneer publishes 2021 Annual and Sustainability Reports

Stockholm, Sweden, February 18, 2022: The automotive technology company Veoneer, Inc. (NYSE: VNE and SSE: VNE SDB), has filed its 2021 Annual Report on Form 10-K with the Securities and Exchange Commission (SEC).The 2021 Annual Report on Form 10-K is available at the SEC Edgar website: www.sec.gov and on Veoneer’s web site veoneer.com. Veoneer has also published its 2021 Sustainability Report and it is available on Veoneer’s web site veoneer.com. Annual Meeting of ShareholdersThe Board of Directors has set June 2, 2022 as the date for Veoneer's 2022 Annual Meeting of Shareholders to be

Attana has submitted a new patent application

Attana has filed a new patent application with claims for methods for assessing the neutralising potential of antibodies in biological samples. The invention is applicable in both of Attana´s business areas – Life Science and Diagnostics.Attana has filed a new patent application with several claims assessing the neutralising potential of antibodies or other biological entities in complex biological samples. The invention can be applied within diagnostics with the purpose to better determine the immunity of individuals based on several parameters, such as kinetics and titres of immune

There are no items matching the current filter
There are no more items matching the current filter
Back to top